| Website | pulmonx.com |
| Category | BioTech |
| Phone | +1 (650) 364-0400 |
| Employees | |
| Description | minimally-invasive medical devices |
| Total | $63.5M |
| Series B, 5/07 De Novo Ventures Latterell Venture Partners Montreux Equity Partners MedVenture Associates | $20M |
| Unattributed, 1/10 | $11.5M |
| Series C, 3/10 Kleiner Perkins Caufield & Byers De Novo Ventures Latterell Venture Partners MedVenture Associates HealthCap Montreux Equity Partners POSCO BioVentures | $32M |
Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.
The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The company’s Zephyr® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung.
The company has CE mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.
